Arvinas Inc (Arvinas) is a biopharmaceutical company that develops protein degradation therapeutics. The company develops novel therapeutics for the treatment of neuroscience, oncology, and other therapeutic areas. Its pipeline product candidates include ARV-471 for breast cancer, bavdegalutamide (ARV-110) for prostate cancer, and ARV-766 for the treatment of men with mCRPC. Arvinas’s protein degradation technology platform PROTAC Discovery Engine develops proteolysis-targeting chimera, or PROTAC targeted protein degraders, and addresses a broad range of intracellular disease targets. The company intends to expand its transformative protein degradation technology and its product candidates into clinical development through collaborations with pharmaceutical companies. Arnivas is headquartered in New Haven, Connecticut, the US.

Headquarters United States of America

Address 5 Science Park, New Haven, Connecticut, 06511-1966


Telephone 1 203 5351456

No of Employees 280

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange ARVN (NASD)

Revenue (2021) $46.7M 114.2% (2021 vs 2020)

EPS XXX

Net Income (2021) XXX -60.1% (2021 vs 2020)

Market Cap* $2.1B

Net Profit Margin (2021) XXX 25.3% (2021 vs 2020)

* As of and is in US$

Access premium data and analytics for Arvinas Inc

30+

Catalyst Calendar

Proactively evaluate Arvinas Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

30+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Arvinas Inc’s relevant decision makers and contact details.

20+

Pipeline Drugs

Identify which of Arvinas Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

13+

Clinical Trials

Determine Arvinas Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

1

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

40+

Install Base

Install Base provides a holistic and a granular view of the IT product/service deployments from leading vendors. Explore IT infrastructure categories, solution and product/service areas deployed by a prospect.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Arvinas Inc’s likely spend across technology areas enabling you to understand the digital strategy.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products Brands
Pipeline: PROTAC
Bavdegalutamide (ARV-110)
ARV-766
XXX
XXX
XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Contracts/Agreements In October, the company entered into a multi-target collaboration with PhoreMost Ltd, under the agreement, PhoreMost will receive research funding and will be eligible for pre-clinical, clinical, and commercial milestones.
2022 Contracts/Agreements In June, the company and Foundation Medicine Inc collaborated to develop FoundationOne Liquid CDx as a companion diagnostic for use with Arvinas’ bavdegalutamide (ARV-110).
2022 Contracts/Agreements In May, the company entered into a collaboration with GNS Healthcare to accelerate drug development for neurodegenerative diseases.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Arvinas Inc AbbVie Inc Novartis AG GSK plc Bristol-Myers Squibb Co
Headquarters United States of America United States of America Switzerland United Kingdom United States of America
City New Haven North Chicago Basel Brentford New York
State/Province Connecticut Illinois - - New York
No. of Employees 280 50,000 108,000 90,096 32,200
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Timothy Shannon, MD Chairman Executive Board 2013 63
John G. Houston, Ph.D. President; Director; Chief Executive Officer Executive Board 2017 62
Sean Cassidy Chief Financial Officer Senior Management - -
Ronald Peck, M.D. Chief Medical Officer Senior Management - -
Ian Taylor, Ph.D. Chief Scientific Officer Senior Management 2019 -
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company Analytics

Contact the team or request a demo to find out how our data can drive your business forward

Why are you leaving?